Timing Errors May Skew GLP-1RA Cardiovascular Risk Studies, Letter Warns
A letter to the editor in the Journal of Clinical Sleep Medicine warns that misaligned exposure timing may introduce immortal ...
A letter to the editor in the Journal of Clinical Sleep Medicine warns that misaligned exposure timing may introduce immortal ...
A Bayesian re-analysis of six clinical trials estimates that people who stop semaglutide or tirzepatide regain roughly one kilogram per ...
A new meta-analysis finds that combining SGLT2 inhibitors with GLP-1 receptor agonists is associated with lower risks of myocardial infarction ...
An international expert panel calls for MASLD to be managed as a systemic cardiometabolic disease, proposing bidirectional heart–liver screening, fibrosis-based ...
Scientists are taking a hard look at whether the world's most widely prescribed diabetes medications could do far more than ...
GLP-1 receptor agonists, the blockbuster class of drugs behind medications such as semaglutide and liraglutide, have become famous for reshaping ...
The Next Revolution in Obesity Care May Depend on What Happens Beyond the Prescription The rapid rise of glucagon-like peptide-1 ...
A new study published in Nature Communications is putting a widely used class of diabetes medicines under the microscope, asking ...
For decades, obesity medicines were judged largely by how effectively they reduced appetite. Many could help people lose weight, but ...
Generic semaglutide is starting to rewrite the economics of type 2 diabetes care in Canada. A new analysis published in ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine